Ionic liquid versus prodrug strategy to address formulation challenges

Pharmaceutical Research

Volumn 32, Issue 6, 2015, Pages 2154-2167

  Balk, Anja ^a   Widmer, Toni ^a,b   Wiest, Johannes ^a   Bruhn, Heike ^c   Rybak, Jens Christoph ^a   Matthes, Philipp ^a   Müller Buschbaum, Klaus ^a   Sakalis, Anastasios ^a   Lühmann, Tessa ^a   Berghausen, Jörg ^b   Holzgrabe, Ulrike ^a   Galli, Bruno ^b   Meinel, Lorenz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Active pharmaceutical ingredient; Bioavailability; Ionic liquid; Mechanismof supersaturation; Migraine

Indexed keywords

COUNTERION; IONIC LIQUID; PRODRUG; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR;

ARTICLE; CELL MEMBRANE PERMEABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYSTAL; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFRARED RADIATION; INTERMETHOD COMPARISON; KIDNEY CELL; KINETICS; LIVER CELL; MACROPHAGE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERMEABILITY; POWDER DIFFRACTION; PRECIPITATION; PRIORITY JOURNAL; SOLID STATE; SOLUBILITY; SUSPENSION; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CACO 2 CELL LINE; CHEMISTRY; COMPARATIVE STUDY; INFRARED SPECTROPHOTOMETRY; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; IONIC LIQUIDS; MAGNETIC RESONANCE SPECTROSCOPY; PERMEABILITY; POWDER DIFFRACTION; PRODRUGS; RECEPTORS, AMPA; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 84930683402     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1607-9     Document Type: Article

References (34)

1. Miller DA, Watts AB, Williams III RO. Formulating poorly water soluble drugs. New York: Springer; 2012.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev. 1997;23:3-25.
3. Johnson KE. What's an ionic liquid? Electrochem Soc Interface. 2007;16:38-41.
4. D.R. MacFarlane, J.M. Pringle, K.M. Johansson, S.A. Forsyth, and M. Forsyth. Lewis base ionic liquids. Chem Commun (Camb):1905-1917 (2006).
5. Hough WL, Smiglak M, Rodriguez H, Swatloski RP, Spear SK, Daly DT, et al. The third evolution of ionic liquids: active pharmaceutical ingredients. New J Chem. 2007;31:1429-36.
6. Stellaand VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Delivery Rev. 2007;59:677-94.
7. Russo E, Gitto R, Citraro R, Chimirri A, De SG. New AMPA antagonists in epilepsy. Expert Opin Invest Drugs. 2012;21:1371-89.
8. Orain D, Ofner S, Koller M, Carcache DA, Froestl W, Allgeier H, et al. 6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2012;22:996-9.
9. Koller M, Lingenhoehl K, Schmutz M, Vranesic I-T, Kallen J, Auberson YP, et al. Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity. Bioorg Med Chem Lett. 2011;21:3358-61.
10. B. Gomez-Mancilla, R. Brand, T.P. Jurgens, H. Gobel, C. Sommer, A. Straube, S. Evers, M. Sommer, V. Campos, H.O. Kalkman, S. Hariry, N. Pezous, D. Johns, and H.-C. Diener. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia (2013).
11. Ahmed R, Gogal M, Walsh JE. A new rapid and simple nonradioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994;170:211-24.
12. Hsieh Y-L, Ilevbare GA, Van EB, Box KJ, Sanchez-Felix MV, Taylor LS. pH-induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res. 2012;29:2738-53.
13. Dorbritz S, Ruth W, Kragl U. Investigation on aggregate formation of ionic liquids. Adv Synth Catal. 2005;347:1273-9.
14. LaPlante SR, Carson R, Gillard J, Aubry N, Coulombe R, Bordeleau S, et al. Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists. J Med Chem. 2013;56:5142-50.
15. Imai T, Sakai M, Ohtake H, Azuma H, Otagiri M. In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm Res. 1999;16:80-6.
16. Davey RJ, Schroeder SL, ter Horst JH. Nucleation of organic crystals-a molecular perspective. Angew Chem Int Ed Engl. 2013;52:2166-79.
17. M. Volmerand Editor. Die chemische Reaktion. Bd. IV. Kinetik der Phasenbildung, J. W. Edwards (1939).
18. Kashchiev D, van Rosmalem GM. Review: nucleation in solutions revisited. Cryst Res Technol. 2003;38:555-74.
19. Sangwal K. Nucleation: basic theory with applications edited by dimo kashchiev. Cryst Res Technol. 2001;36:235.
20. Rodriguez-Hornedo N, Lechuga-Ballesteros D, Wu HJ. Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int J Pharm. 1992;85:149-62.
21. Stevenson CL, Bennett DB, Lechuga-Ballesteros D. Pharmaceutical liquid crystals: the relevance of partially ordered systems. J Pharm Sci. 2005;94:1861-80.
22. Dunn BJ, Nichols CW, Gad SC. Acute dermal toxicity of two quaternary organophosphonium salts in the rabbit. Toxicology. 1982;24:245-50.
23. Bica K, Rijksen C, Nieuwenhuyzen M, Rogers RD. In search of pure liquid salt forms of aspirin: ionic liquid approaches with acetylsalicylic acid and salicylic acid. Phys Chem Chem Phys. 2010;12:2011-7.
24. Stuartand M, Box K. Chasing equilibrium: measuring the intrinsic solubility of weak acids and bases. Anal Chem. 2005;77:983-90.
25. Gravestock T, Box K, Comer J, Frake E, Judge S, Ruiz R. The "GI dissolution" method: a low volume, in vitro apparatus for assessing the dissolution/precipitation behaviour of an active pharmaceutical ingredient under biorelevant conditions. Anal Methods. 2011;3:560-7.
26. Sheldrick GM. A short history of SHELX. Acta crystallographica section A. Foundations of crystallography. 2008;64:112-22.
27. Spek AL. Structure validation in chemical crystallography. Acta crystallographica section D. Biological crystallography. 2009;65: 148-55.
28. Barbour LJ. X-seed - a software tool for supramolecular crystallography. J Supramol Chem. 2003;1:189-91.
29. Dolomanov OV, Bourhis LJ, Gildea RJ, Howard JAK, Puschmann H. OLEX2: a complete structure solution, refinement and analysis program. J Appl Cryst. 2009;4:339-41.
30. Gozzo FC, Santos LS, Augusti R, Consorti CS, Dupont J, Eberlin MN. Gaseous supramolecules of imidazolium ionic liquids: "Magic" numbers and intrinsic strengths of hydrogen bonds. Chem Eur J. 2004;10:6187-93.
31. Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle HP, et al. Transport of alkamides from Echinacea species through Caco-2 monolayers. Planta Med. 2002;68:469-71.
32. Hubatsch I, Ragnarsson EG, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007;2:2111-9.
33. Masungi C, Borremans C, Willems B, Mensch J, Van Dijck A, Augustijns P, et al. Usefulness of a novel Caco-2 cell perfusion system. I. In vitro prediction of the absorption potential of passively diffused compounds. J Pharm Sci. 2004;93:2507-21.
34. Hakala K, Laitinen L, Kuakonen AM, Hirvonen J, Kostiainen R, Kotiaho T. Development of fast LC/MS/MS methods for cocktail dosed Caco-2 samples using atmospheric pressure photoionization (APPI) and electrospray ionization (ESI). Eur J Pharm Sci. 2003;19: S30-30.